Salvage chemotherapy in recurrent cervical cancer with biweekly pegylated Liposomal Doxorubicin (Lipo-Dox)

Taiwanese Journal of Obstetrics and Gynecology

Volumn 47, Issue 3, 2008, Pages 322-326

  Chen, Jen Ruei ^a   Yang, Yuh Cheng ^a,b   Chen, Tze Chien ^a   Lai, Jerry Cheng Yen ^a   Chang, Shing Jyh ^a,c   Chang, Chi Long ^a   Wang, Kung Liahng ^a,d  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^d NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

Author keywords

Cervical cancer; Chemotherapy; Lipo Dox; Liposomal doxorubicin; Recurrent

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GLUCOSE; IFOSFAMIDE; LIPO DOX; METHOTREXATE; PACLITAXEL; PLATINUM; UNCLASSIFIED DRUG; VINCRISTINE;

ABDOMINAL HYSTERECTOMY; ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER STAGING; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; PELVIS LYMPHADENECTOMY; PHASE 2 CLINICAL TRIAL; RADICAL HYSTERECTOMY; RECURRENT CANCER; SALVAGE THERAPY; SURVIVAL TIME; THERAPY DELAY; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

EID: 56749104224     PISSN: 10284559     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1028-4559(08)60132-1     Document Type: Article

References (20)

1. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
2. Chen HS, Yang YC, Su TH, Wang TY, Huang YW. Human papillomavirus testing (hybrid capture II) to detect high-grade cervical intraepithelial neoplasia in women with mildly abnormal papanicolaou results. Taiwan J Obstet Gynecol 2005;44:252-7.
3. Cheng WF. Human papillomavirus vaccine for cervical cancer: where are we now? Taiwan J Obstet Gynecol 2005; 44:232-41.
4. Wang PD, Lin RS. Epidemiology of cervical cancer in Taiwan. Gynecol Oncol 1996;62:344-52.
5. Bureau of Health Promotion, Department of Health, Taiwan. November 16, 2006. Available at: http://www.bhp.doh.gov.tw/asp/themeParkld=510/960305/ pdf/951116.pdf [Date accessed: March 22, 2007]
6. Tseng CC, Tseng CJ, Chang CC, et al. Human papillomavirus deoxyribonucleic acid sequences and clinical outcomes of cervical cancer patients following radiotherapy. Taiwan J Obstet Gynecol 2004;43:20-4.
7. Tambaro R, Scambia G, Di Maio M, Pisano C, Barletta E, Iaffaioli VR, Pignata S. The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. Crit Rev Oncol Hematol 2004;52:33-44.
8. Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature 1996;380:561-2.
9. Verschraegen CF, Kavanagh JJ, Loyer E, et al; Community Clinical Oncology Program. Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix. Cancer 2001;92:2327-33.
10. O'Byrne KJ, Bliss P, Graham JD, et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer. Proc Am Soc Clin Oncol 2002; 21:203a. [Abstract 808]
11. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22.
12. Gordon AN, Tonda M, Sun S, Rackoff W; Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95:1-8.
13. Woll PJ, Carmichael J, Chan S, Howell A, Ranson M, Miles D, Welbank H. Phase II study results on safety and tolerability of Caelyx® (Doxil®) in combination with paclitaxel in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 1999:18:117a. [Abstract 442]
14. Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 1995;13:914-20.
15. Chou HH, Wang KL, Chen CA, et al; Taiwanese Gynecologic Oncology Group. Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up. Gynecol Oncol 2006; 101:423-8.
16. Lorusso D, Naldini A, Testa A, D'Agostino G, Scambia G, Ferrandina G. Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. Oncology 2004;67:243-9.
17. Martin FJ, Gabizon A, et al. Human pharmacokinetics of stealth liposomes containing doxorubicin. J Cell Biochem 1992;50(Suppl 16E):98.
18. Gabizon A. Liposomal anthracyclines. Hematol Oncol Clin North Am 1994;8:431-50.
19. Ferrandina G, Lorusso D, Longo R, Testa AC, Scambia G. Pegylated liposomal doxorubicin in platinum-treated recurrent or metastatic cervical carcinoma. Gynecol Oncol 2005; 98:332-3.
20. Rose PG, Blessing JA, Lele S, Abulafia O. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006;102:210-3.